ZA200301719B - Quinoline and quinazoline derivatives as ligands for the neuropeptide Y receptor. - Google Patents

Quinoline and quinazoline derivatives as ligands for the neuropeptide Y receptor. Download PDF

Info

Publication number: ZA200301719B
Authority: ZA; South Africa
Prior art keywords: methyl; phenyl; pyrrolidin; quinoline; composition
Prior art date: 2000-09-06

Application number

ZA200301719A

Other languages

English (en)

Inventor

Volker Breu

Frank Dautzenberg

Philippe Guerry

Matthias-Heinrich Nettekoven

Philippe Pflieger

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-06

Filing date

2003-02-28

Publication date

2004-06-22

2003-02-28 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-06-22 Publication of ZA200301719B publication Critical patent/ZA200301719B/en

Links

SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title claims description 10
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title claims description 4
239000003446 ligand Substances 0.000 title description 4
108050002826 Neuropeptide Y Receptor Proteins 0.000 title 1
102000012301 Neuropeptide Y receptor Human genes 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 129
-1 methylendioxy Chemical group 0.000 claims description 60
125000000217 alkyl group Chemical group 0.000 claims description 42
238000000034 method Methods 0.000 claims description 33
239000000203 mixture Substances 0.000 claims description 32
238000011282 treatment Methods 0.000 claims description 30
238000006243 chemical reaction Methods 0.000 claims description 29
150000003839 salts Chemical class 0.000 claims description 25
239000000126 substance Substances 0.000 claims description 23
229940086609 Lipase inhibitor Drugs 0.000 claims description 21
125000003545 alkoxy group Chemical group 0.000 claims description 19
208000008589 Obesity Diseases 0.000 claims description 18
235000020824 obesity Nutrition 0.000 claims description 18
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 16
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 16
229960001243 orlistat Drugs 0.000 claims description 15
238000011321 prophylaxis Methods 0.000 claims description 15
125000001544 thienyl group Chemical group 0.000 claims description 15
150000002148 esters Chemical class 0.000 claims description 14
229910052736 halogen Inorganic materials 0.000 claims description 14
150000002367 halogens Chemical class 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 14
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
125000001424 substituent group Chemical group 0.000 claims description 13
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
125000004076 pyridyl group Chemical group 0.000 claims description 12
208000024172 Cardiovascular disease Diseases 0.000 claims description 11
208000030814 Eating disease Diseases 0.000 claims description 11
208000019454 Feeding and Eating disease Diseases 0.000 claims description 11
208000001647 Renal Insufficiency Diseases 0.000 claims description 11
206010003246 arthritis Diseases 0.000 claims description 11
206010012601 diabetes mellitus Diseases 0.000 claims description 11
235000014632 disordered eating Nutrition 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
201000006370 kidney failure Diseases 0.000 claims description 11
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 10
229910052794 bromium Inorganic materials 0.000 claims description 10
125000004093 cyano group Chemical group *C#N 0.000 claims description 10
230000008569 process Effects 0.000 claims description 10
239000012453 solvate Substances 0.000 claims description 10
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
239000000460 chlorine Substances 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 9
125000000753 cycloalkyl group Chemical group 0.000 claims description 9
125000001624 naphthyl group Chemical group 0.000 claims description 9
125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
101710151321 Melanostatin Proteins 0.000 claims description 8
102100028427 Pro-neuropeptide Y Human genes 0.000 claims description 8
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 7
125000001041 indolyl group Chemical group 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
238000002560 therapeutic procedure Methods 0.000 claims description 7
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
125000003710 aryl alkyl group Chemical group 0.000 claims description 6
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
229910052723 transition metal Inorganic materials 0.000 claims description 6
150000003624 transition metals Chemical class 0.000 claims description 6
125000004950 trifluoroalkyl group Chemical group 0.000 claims description 6
MPAWSOPNRWJEAL-UHFFFAOYSA-N 7-(3-chlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C=CC=3)=CC2=NC(C)=CC=1N1CCCC1 MPAWSOPNRWJEAL-UHFFFAOYSA-N 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
125000004104 aryloxy group Chemical group 0.000 claims description 5
125000003725 azepanyl group Chemical group 0.000 claims description 5
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
WLHTVHLJGMWRLP-UHFFFAOYSA-N 1-[4-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 WLHTVHLJGMWRLP-UHFFFAOYSA-N 0.000 claims description 4
QHMXVJPBDHKSNO-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-thiophen-2-ylquinoline Chemical compound C=12C=CC(C=3SC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 QHMXVJPBDHKSNO-UHFFFAOYSA-N 0.000 claims description 4
OXHZRYAWIMZYBS-UHFFFAOYSA-N 2-methyl-7-pyridin-3-yl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=NC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 OXHZRYAWIMZYBS-UHFFFAOYSA-N 0.000 claims description 4
ASAMDAHECQCGAB-UHFFFAOYSA-N 7-(4-methoxyphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 ASAMDAHECQCGAB-UHFFFAOYSA-N 0.000 claims description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 4
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 4
125000004414 alkyl thio group Chemical group 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 4
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
PBTSUCHVZHEYFX-UHFFFAOYSA-N 1-[3-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C=2C=C3N=C(C)N=C(C3=CC=2)N2CCCC2)=C1 PBTSUCHVZHEYFX-UHFFFAOYSA-N 0.000 claims description 3
ZEHYSJACCJZZFU-UHFFFAOYSA-N 2-methoxy-4-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenol Chemical compound C1=C(O)C(OC)=CC(C=2C=C3N=C(C)C=C(C3=CC=2)N2CCCC2)=C1 ZEHYSJACCJZZFU-UHFFFAOYSA-N 0.000 claims description 3
ZKDKANVEYYIOHT-UHFFFAOYSA-N 2-methyl-4-piperidin-1-yl-7-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCCC1 ZKDKANVEYYIOHT-UHFFFAOYSA-N 0.000 claims description 3
YHOOHRCDOSVZAJ-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[3-(trifluoromethyl)phenyl]quinazoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=NC=1N1CCCC1 YHOOHRCDOSVZAJ-UHFFFAOYSA-N 0.000 claims description 3
GWRLSUAPTXQGQZ-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCC1 GWRLSUAPTXQGQZ-UHFFFAOYSA-N 0.000 claims description 3
DVUXOKQEIGQWDI-UHFFFAOYSA-N 2-methyl-7-naphthalen-2-yl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C4C=CC=CC4=CC=3)=CC2=NC(C)=CC=1N1CCCC1 DVUXOKQEIGQWDI-UHFFFAOYSA-N 0.000 claims description 3
VHRDDHZYCJGTHE-UHFFFAOYSA-N 3-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)benzonitrile Chemical compound C=12C=CC(C=3C=C(C=CC=3)C#N)=CC2=NC(C)=NC=1N1CCCC1 VHRDDHZYCJGTHE-UHFFFAOYSA-N 0.000 claims description 3
IBDGJNBACMWLOR-UHFFFAOYSA-N 4-(azepan-1-yl)-2-methyl-7-[3-(trifluoromethyl)phenyl]quinazoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=NC=1N1CCCCCC1 IBDGJNBACMWLOR-UHFFFAOYSA-N 0.000 claims description 3
HNZFUPVFLZIPGY-UHFFFAOYSA-N 4-(azepan-1-yl)-2-methyl-7-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCCCC1 HNZFUPVFLZIPGY-UHFFFAOYSA-N 0.000 claims description 3
DEHDCLRPFIWCER-UHFFFAOYSA-N 5-(3-chlorophenyl)-2-methyl-4-piperidin-1-ylquinoline Chemical compound C=12C(C=3C=C(Cl)C=CC=3)=CC=CC2=NC(C)=CC=1N1CCCCC1 DEHDCLRPFIWCER-UHFFFAOYSA-N 0.000 claims description 3
WKPACHADPWHREV-UHFFFAOYSA-N 7-(3,4-dichlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C(Cl)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 WKPACHADPWHREV-UHFFFAOYSA-N 0.000 claims description 3
GGSPYNHXXJFFLS-UHFFFAOYSA-N 7-(3,5-dichlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C=C(Cl)C=3)=CC2=NC(C)=CC=1N1CCCC1 GGSPYNHXXJFFLS-UHFFFAOYSA-N 0.000 claims description 3
DTYNDESCRADOCW-UHFFFAOYSA-N 7-(3-chloro-4-fluorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C(F)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 DTYNDESCRADOCW-UHFFFAOYSA-N 0.000 claims description 3
FIQCWGFEPZLCIE-UHFFFAOYSA-N 7-(3-chlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinazoline Chemical compound C=12C=CC(C=3C=C(Cl)C=CC=3)=CC2=NC(C)=NC=1N1CCCC1 FIQCWGFEPZLCIE-UHFFFAOYSA-N 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 3
238000006880 cross-coupling reaction Methods 0.000 claims description 3
125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 3
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 2
239000011541 reaction mixture Substances 0.000 description 17
125000004435 hydrogen atom Chemical class [H]* 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
229910052757 nitrogen Inorganic materials 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
238000009835 boiling Methods 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 7
239000006260 foam Substances 0.000 description 7
239000007903 gelatin capsule Substances 0.000 description 7
229910052763 palladium Inorganic materials 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000027455 binding Effects 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
125000001153 fluoro group Chemical group F* 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
101100460785 Mus musculus Npy5r gene Proteins 0.000 description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
230000037406 food intake Effects 0.000 description 5
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
229920005862 polyol Polymers 0.000 description 5
150000003077 polyols Chemical class 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
102000004882 Lipase Human genes 0.000 description 4
108090001060 Lipase Proteins 0.000 description 4
239000004367 Lipase Substances 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
125000001309 chloro group Chemical group Cl* 0.000 description 4
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
239000008298 dragée Substances 0.000 description 4
239000003925 fat Substances 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
239000011737 fluorine Substances 0.000 description 4
235000012631 food intake Nutrition 0.000 description 4
125000000623 heterocyclic group Chemical group 0.000 description 4
239000011630 iodine Substances 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
235000019421 lipase Nutrition 0.000 description 4
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
RLQMWXGYEFKSKO-UHFFFAOYSA-N 2-methyl-7-phenyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=CC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 RLQMWXGYEFKSKO-UHFFFAOYSA-N 0.000 description 3
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 3
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010020710 Hyperphagia Diseases 0.000 description 3
SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 3
102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 3
101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 description 3
102100029909 Peptide YY Human genes 0.000 description 3
108010088847 Peptide YY Proteins 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 3
229910052759 nickel Inorganic materials 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
239000011734 sodium Substances 0.000 description 3
235000015112 vegetable and seed oil Nutrition 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
239000001993 wax Substances 0.000 description 3
230000004584 weight gain Effects 0.000 description 3
235000019786 weight gain Nutrition 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
GPEFEZMRLVVQIS-UHFFFAOYSA-N 2-methyl-7-pyrimidin-5-yl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=NC=NC=3)=CC2=NC(C)=CC=1N1CCCC1 GPEFEZMRLVVQIS-UHFFFAOYSA-N 0.000 description 2
VZDWRTSTRRUUAA-UHFFFAOYSA-N 3-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)aniline Chemical compound C=12C=CC(C=3C=C(N)C=CC=3)=CC2=NC(C)=CC=1N1CCCC1 VZDWRTSTRRUUAA-UHFFFAOYSA-N 0.000 description 2
WUKXTJQCEGKRDX-UHFFFAOYSA-N 7-iodo-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(I)=CC2=NC(C)=CC=1N1CCCC1 WUKXTJQCEGKRDX-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229940127470 Lipase Inhibitors Drugs 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
102000028582 Neuropeptide Y5 receptor Human genes 0.000 description 2
108090000189 Neuropeptides Proteins 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
150000008041 alkali metal carbonates Chemical class 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000021407 appetite control Nutrition 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
125000002757 morpholinyl group Chemical group 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
125000001302 tertiary amino group Chemical group 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 1
VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
TVFOWSHXUQBNOM-UHFFFAOYSA-N 1-[4-(2-methyl-4-piperidin-1-ylquinolin-7-yl)phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCCC3)C2=C1 TVFOWSHXUQBNOM-UHFFFAOYSA-N 0.000 description 1
LLCVSWQQKQJENV-UHFFFAOYSA-N 1-[4-[4-(diethylamino)-2-methylquinolin-7-yl]phenyl]ethanone Chemical compound C=1C=C2C(N(CC)CC)=CC(C)=NC2=CC=1C1=CC=C(C(C)=O)C=C1 LLCVSWQQKQJENV-UHFFFAOYSA-N 0.000 description 1
OKZMCFQJUDXOHG-UHFFFAOYSA-N 1-[5-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC=C1C1=CC=C(C(=NC(C)=N2)N3CCCC3)C2=C1 OKZMCFQJUDXOHG-UHFFFAOYSA-N 0.000 description 1
SVQUONYNVYWPAQ-UHFFFAOYSA-N 1-[5-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 SVQUONYNVYWPAQ-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
OABZENZKEHFAGF-UHFFFAOYSA-N 2-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenol Chemical compound C=12C=CC(C=3C(=CC=CC=3)O)=CC2=NC(C)=CC=1N1CCCC1 OABZENZKEHFAGF-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
PDRCYRWNCFPXTP-UHFFFAOYSA-N 2-methoxy-5-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenol Chemical compound C1=C(O)C(OC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 PDRCYRWNCFPXTP-UHFFFAOYSA-N 0.000 description 1
IZCVPUPSLZQQBK-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-7-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C1CN(C)CCN1C1=CC(C)=NC2=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC=C12 IZCVPUPSLZQQBK-UHFFFAOYSA-N 0.000 description 1
XGRLXFYQPNAKNQ-UHFFFAOYSA-N 2-methyl-4-piperidin-1-yl-5-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C=12C(C=3C=C(C=CC=3)C(F)(F)F)=CC=CC2=NC(C)=CC=1N1CCCCC1 XGRLXFYQPNAKNQ-UHFFFAOYSA-N 0.000 description 1
IFOGDZIGIUSBFF-UHFFFAOYSA-N 2-methyl-4-piperidin-1-yl-7-[3-(trifluoromethyl)phenyl]quinazoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=NC=1N1CCCCC1 IFOGDZIGIUSBFF-UHFFFAOYSA-N 0.000 description 1
GVXGICXHLZJGDH-UHFFFAOYSA-N 2-methyl-4-piperidin-1-yl-7-pyridin-3-ylquinazoline Chemical compound C=12C=CC(C=3C=NC=CC=3)=CC2=NC(C)=NC=1N1CCCCC1 GVXGICXHLZJGDH-UHFFFAOYSA-N 0.000 description 1
HULFTQHILMLTNI-UHFFFAOYSA-N 2-methyl-4-piperidin-1-yl-7-pyridin-3-ylquinoline Chemical compound C=12C=CC(C=3C=NC=CC=3)=CC2=NC(C)=CC=1N1CCCCC1 HULFTQHILMLTNI-UHFFFAOYSA-N 0.000 description 1
UVXSABPUEFYSQJ-UHFFFAOYSA-N 2-methyl-4-piperidin-1-yl-7-thiophen-2-ylquinoline Chemical compound C=12C=CC(C=3SC=CC=3)=CC2=NC(C)=CC=1N1CCCCC1 UVXSABPUEFYSQJ-UHFFFAOYSA-N 0.000 description 1
RGINZCQGPKVTHJ-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[2-(trifluoromethoxy)phenyl]quinoline Chemical compound C=12C=CC(C=3C(=CC=CC=3)OC(F)(F)F)=CC2=NC(C)=CC=1N1CCCC1 RGINZCQGPKVTHJ-UHFFFAOYSA-N 0.000 description 1
DNLXQELIUSGWAR-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[3-(trifluoromethoxy)phenyl]quinazoline Chemical compound C=12C=CC(C=3C=C(OC(F)(F)F)C=CC=3)=CC2=NC(C)=NC=1N1CCCC1 DNLXQELIUSGWAR-UHFFFAOYSA-N 0.000 description 1
CVZWYUSWIVHAGR-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[3-(trifluoromethoxy)phenyl]quinoline Chemical compound C=12C=CC(C=3C=C(OC(F)(F)F)C=CC=3)=CC2=NC(C)=CC=1N1CCCC1 CVZWYUSWIVHAGR-UHFFFAOYSA-N 0.000 description 1
QMLZFEGJZZMNEO-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[4-(trifluoromethoxy)phenyl]quinoline Chemical compound C=12C=CC(C=3C=CC(OC(F)(F)F)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 QMLZFEGJZZMNEO-UHFFFAOYSA-N 0.000 description 1
MZUJPBJVZLWPSD-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[4-(trifluoromethyl)phenyl]quinazoline Chemical compound C=12C=CC(C=3C=CC(=CC=3)C(F)(F)F)=CC2=NC(C)=NC=1N1CCCC1 MZUJPBJVZLWPSD-UHFFFAOYSA-N 0.000 description 1
GFTJCSMWHIMNSN-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-[4-(trifluoromethyl)phenyl]quinoline Chemical compound C=12C=CC(C=3C=CC(=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCC1 GFTJCSMWHIMNSN-UHFFFAOYSA-N 0.000 description 1
BSLIAXMITANGRT-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-thiophen-2-ylquinazoline Chemical compound C=12C=CC(C=3SC=CC=3)=CC2=NC(C)=NC=1N1CCCC1 BSLIAXMITANGRT-UHFFFAOYSA-N 0.000 description 1
QJRNKMULYCZDSP-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-7-thiophen-3-ylquinazoline Chemical compound C=12C=CC(C3=CSC=C3)=CC2=NC(C)=NC=1N1CCCC1 QJRNKMULYCZDSP-UHFFFAOYSA-N 0.000 description 1
NTWNATDBCDTKHS-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC=CC2=NC(C)=CC=1N1CCCC1 NTWNATDBCDTKHS-UHFFFAOYSA-N 0.000 description 1
ZMSQYVBTBZSSNE-UHFFFAOYSA-N 2-methyl-7-(3-nitrophenyl)-4-pyrrolidin-1-ylquinazoline Chemical compound C=12C=CC(C=3C=C(C=CC=3)[N+]([O-])=O)=CC2=NC(C)=NC=1N1CCCC1 ZMSQYVBTBZSSNE-UHFFFAOYSA-N 0.000 description 1
OOIUZFASYNUNHR-UHFFFAOYSA-N 2-methyl-7-(4-methylsulfanylphenyl)-4-pyrrolidin-1-ylquinoline Chemical compound C1=CC(SC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 OOIUZFASYNUNHR-UHFFFAOYSA-N 0.000 description 1
NQTHTQOQUGALKS-UHFFFAOYSA-N 2-methyl-7-(4-phenoxyphenyl)-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 NQTHTQOQUGALKS-UHFFFAOYSA-N 0.000 description 1
ZNCDDJWIVJHPLE-UHFFFAOYSA-N 2-methyl-7-naphthalen-1-yl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C4=CC=CC=C4C=CC=3)=CC2=NC(C)=CC=1N1CCCC1 ZNCDDJWIVJHPLE-UHFFFAOYSA-N 0.000 description 1
HYNJOLTUVGLWKW-UHFFFAOYSA-N 2-methyl-7-phenyl-4-piperidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=CC=CC=3)=CC2=NC(C)=CC=1N1CCCCC1 HYNJOLTUVGLWKW-UHFFFAOYSA-N 0.000 description 1
JPCLTLRDMHZBCF-UHFFFAOYSA-N 2-methyl-7-pyrimidin-5-yl-4-pyrrolidin-1-ylquinazoline Chemical compound C=12C=CC(C=3C=NC=NC=3)=CC2=NC(C)=NC=1N1CCCC1 JPCLTLRDMHZBCF-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-M 2-methylbutyrate Chemical compound CCC(C)C([O-])=O WLAMNBDJUVNPJU-UHFFFAOYSA-M 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
JWKIBLYWKJBSQP-UHFFFAOYSA-N 2-piperidin-1-ylquinoline Chemical compound C1CCCCN1C1=CC=C(C=CC=C2)C2=N1 JWKIBLYWKJBSQP-UHFFFAOYSA-N 0.000 description 1
ZUUZNOFTKGDLLN-UHFFFAOYSA-N 3-(1,3,2-dioxaborinan-2-yl)pyridine Chemical compound O1CCCOB1C1=CC=CN=C1 ZUUZNOFTKGDLLN-UHFFFAOYSA-N 0.000 description 1
PEKDRUGJQBMUIY-UHFFFAOYSA-N 3-(2-methyl-4-piperidin-1-ylquinazolin-7-yl)aniline Chemical compound C=12C=CC(C=3C=C(N)C=CC=3)=CC2=NC(C)=NC=1N1CCCCC1 PEKDRUGJQBMUIY-UHFFFAOYSA-N 0.000 description 1
AJWNMNLNLDUHIG-UHFFFAOYSA-N 3-(2-methyl-4-piperidin-1-ylquinolin-7-yl)aniline Chemical compound C=12C=CC(C=3C=C(N)C=CC=3)=CC2=NC(C)=CC=1N1CCCCC1 AJWNMNLNLDUHIG-UHFFFAOYSA-N 0.000 description 1
SWGFAKHIQADZLK-UHFFFAOYSA-N 3-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)aniline Chemical compound C=12C=CC(C=3C=C(N)C=CC=3)=CC2=NC(C)=NC=1N1CCCC1 SWGFAKHIQADZLK-UHFFFAOYSA-N 0.000 description 1
PHHNKGMJFUTIAJ-UHFFFAOYSA-N 3-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)phenol Chemical compound C=12C=CC(C=3C=C(O)C=CC=3)=CC2=NC(C)=NC=1N1CCCC1 PHHNKGMJFUTIAJ-UHFFFAOYSA-N 0.000 description 1
UQSICDQCIUOWPX-UHFFFAOYSA-N 3-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenol Chemical compound C=12C=CC(C=3C=C(O)C=CC=3)=CC2=NC(C)=CC=1N1CCCC1 UQSICDQCIUOWPX-UHFFFAOYSA-N 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
VBFVGHZEQTWSBE-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-2-methyl-7-[3-(trifluoromethyl)phenyl]quinoline Chemical compound C=1C2=NC(C)=CC(N3CC4=CC=CC=C4CC3)=C2C=CC=1C1=CC=CC(C(F)(F)F)=C1 VBFVGHZEQTWSBE-UHFFFAOYSA-N 0.000 description 1
QJYKPEUTMVFMTK-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-7-iodo-2-methylquinoline;hydrochloride Chemical compound Cl.C1=CC(I)=CC2=NC(C)=CC(N3CC4=CC=CC=C4CC3)=C21 QJYKPEUTMVFMTK-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
ICCRBEFQBDIMLF-UHFFFAOYSA-N 4-(5-iodo-2-methylquinolin-4-yl)morpholine Chemical compound C=12C(I)=CC=CC2=NC(C)=CC=1N1CCOCC1 ICCRBEFQBDIMLF-UHFFFAOYSA-N 0.000 description 1
NCEYZSFGLZRVLZ-UHFFFAOYSA-N 4-(7-iodo-2-methylquinolin-4-yl)morpholine Chemical compound C=12C=CC(I)=CC2=NC(C)=CC=1N1CCOCC1 NCEYZSFGLZRVLZ-UHFFFAOYSA-N 0.000 description 1
GSBYABDILMZERW-UHFFFAOYSA-N 4-(azepan-1-yl)-7-bromo-2-methylquinazoline Chemical compound C=12C=CC(Br)=CC2=NC(C)=NC=1N1CCCCCC1 GSBYABDILMZERW-UHFFFAOYSA-N 0.000 description 1
LEHMFQMPEDAKCH-UHFFFAOYSA-N 4-(azepan-1-yl)-7-iodo-2-methylquinoline Chemical compound C=12C=CC(I)=CC2=NC(C)=CC=1N1CCCCCC1 LEHMFQMPEDAKCH-UHFFFAOYSA-N 0.000 description 1
WHNVWTIQHTWJPY-UHFFFAOYSA-N 4-(azetidin-1-yl)-7-bromo-2-methylquinazoline Chemical compound C=12C=CC(Br)=CC2=NC(C)=NC=1N1CCC1 WHNVWTIQHTWJPY-UHFFFAOYSA-N 0.000 description 1
DSNDHKJQAWWIHN-UHFFFAOYSA-N 4-[2-methyl-7-[3-(trifluoromethyl)phenyl]quinolin-4-yl]morpholine Chemical compound C=12C=CC(C=3C=C(C=CC=3)C(F)(F)F)=CC2=NC(C)=CC=1N1CCOCC1 DSNDHKJQAWWIHN-UHFFFAOYSA-N 0.000 description 1
MNGGPYUDHXZYBD-UHFFFAOYSA-N 4-[5-(3-chlorophenyl)-2-methylquinolin-4-yl]morpholine Chemical compound C=12C(C=3C=C(Cl)C=CC=3)=CC=CC2=NC(C)=CC=1N1CCOCC1 MNGGPYUDHXZYBD-UHFFFAOYSA-N 0.000 description 1
GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 1
KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 1
RGNKFIPGBOGYCA-UHFFFAOYSA-N 5-(3-chlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C(C=3C=C(Cl)C=CC=3)=CC=CC2=NC(C)=CC=1N1CCCC1 RGNKFIPGBOGYCA-UHFFFAOYSA-N 0.000 description 1
UKJXQSNISMUMND-UHFFFAOYSA-N 5-iodo-2-methyl-4-piperidin-1-ylquinoline Chemical compound C=12C(I)=CC=CC2=NC(C)=CC=1N1CCCCC1 UKJXQSNISMUMND-UHFFFAOYSA-N 0.000 description 1
AWKSSRXXXKLAAT-UHFFFAOYSA-N 5-iodo-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C(I)=CC=CC2=NC(C)=CC=1N1CCCC1 AWKSSRXXXKLAAT-UHFFFAOYSA-N 0.000 description 1
VVKSNZZNTDIDOB-UHFFFAOYSA-N 6-(3-chlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=C(C=3C=C(Cl)C=CC=3)C=CC2=NC(C)=CC=1N1CCCC1 VVKSNZZNTDIDOB-UHFFFAOYSA-N 0.000 description 1
MZUBHXZWTGPFID-UHFFFAOYSA-N 6-bromo-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=C(Br)C=CC2=NC(C)=CC=1N1CCCC1 MZUBHXZWTGPFID-UHFFFAOYSA-N 0.000 description 1
OCNREXWJWVKEEB-UHFFFAOYSA-N 6-bromo-4-chloro-2-methylquinoline Chemical compound C1=C(Br)C=CC2=NC(C)=CC(Cl)=C21 OCNREXWJWVKEEB-UHFFFAOYSA-N 0.000 description 1
VCEHOIJMSHGAOJ-UHFFFAOYSA-N 7-(1-benzofuran-2-yl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3OC4=CC=CC=C4C=3)=CC2=NC(C)=CC=1N1CCCC1 VCEHOIJMSHGAOJ-UHFFFAOYSA-N 0.000 description 1
VTVJLPOENSRPPK-UHFFFAOYSA-N 7-(1-benzothiophen-2-yl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3SC4=CC=CC=C4C=3)=CC2=NC(C)=CC=1N1CCCC1 VTVJLPOENSRPPK-UHFFFAOYSA-N 0.000 description 1
PUUDNEUBAROSKG-UHFFFAOYSA-N 7-(1h-indol-5-yl)-2-methyl-4-piperidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C4C=CNC4=CC=3)=CC2=NC(C)=CC=1N1CCCCC1 PUUDNEUBAROSKG-UHFFFAOYSA-N 0.000 description 1
VHOMAISKOCZXFV-UHFFFAOYSA-N 7-(1h-indol-5-yl)-2-methyl-4-pyrrolidin-1-ylquinazoline Chemical compound C=12C=CC(C=3C=C4C=CNC4=CC=3)=CC2=NC(C)=NC=1N1CCCC1 VHOMAISKOCZXFV-UHFFFAOYSA-N 0.000 description 1
PDIHALUPJSENJO-UHFFFAOYSA-N 7-(2,4-dimethoxyphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound COC1=CC(OC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 PDIHALUPJSENJO-UHFFFAOYSA-N 0.000 description 1
DCOXKKBRFOLPHT-UHFFFAOYSA-N 7-(2,6-dichlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C(=CC=CC=3Cl)Cl)=CC2=NC(C)=CC=1N1CCCC1 DCOXKKBRFOLPHT-UHFFFAOYSA-N 0.000 description 1
JALWPQUUCNQALD-UHFFFAOYSA-N 7-(2-chlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C(=CC=CC=3)Cl)=CC2=NC(C)=CC=1N1CCCC1 JALWPQUUCNQALD-UHFFFAOYSA-N 0.000 description 1
WREJLSXASXWYBQ-UHFFFAOYSA-N 7-(2-fluorophenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C(=CC=CC=3)F)=CC2=NC(C)=CC=1N1CCCC1 WREJLSXASXWYBQ-UHFFFAOYSA-N 0.000 description 1
KALNOVSJMVBHMV-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound COC1=CC=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 KALNOVSJMVBHMV-UHFFFAOYSA-N 0.000 description 1
VYJVIWKHXFICAD-UHFFFAOYSA-N 7-(3,4-dimethoxyphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 VYJVIWKHXFICAD-UHFFFAOYSA-N 0.000 description 1
FHGOSFFAFBWVGF-UHFFFAOYSA-N 7-(3,5-dichlorophenyl)-2-methyl-4-pyrrolidin-1-ylquinazoline Chemical compound C=12C=CC(C=3C=C(Cl)C=C(Cl)C=3)=CC2=NC(C)=NC=1N1CCCC1 FHGOSFFAFBWVGF-UHFFFAOYSA-N 0.000 description 1
CWEMZTGUUPHHOE-UHFFFAOYSA-N 7-(3-aminophenyl)-n,n-diethyl-2-methylquinolin-4-amine Chemical compound C=1C=C2C(N(CC)CC)=CC(C)=NC2=CC=1C1=CC=CC(N)=C1 CWEMZTGUUPHHOE-UHFFFAOYSA-N 0.000 description 1
KFRMHLILVBAGQL-UHFFFAOYSA-N 7-(3-chlorophenyl)-2-methyl-4-piperidin-1-ylquinazoline Chemical compound C=12C=CC(C=3C=C(Cl)C=CC=3)=CC2=NC(C)=NC=1N1CCCCC1 KFRMHLILVBAGQL-UHFFFAOYSA-N 0.000 description 1
HYPQIQDOOQACDE-UHFFFAOYSA-N 7-(3-chlorophenyl)-2-methyl-4-piperidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(Cl)C=CC=3)=CC2=NC(C)=CC=1N1CCCCC1 HYPQIQDOOQACDE-UHFFFAOYSA-N 0.000 description 1
YWBCMEPEHFEXJV-UHFFFAOYSA-N 7-(3-chlorophenyl)-4-pyrrolidin-1-ylquinoline Chemical compound ClC1=CC=CC(C=2C=C3N=CC=C(C3=CC=2)N2CCCC2)=C1 YWBCMEPEHFEXJV-UHFFFAOYSA-N 0.000 description 1
GHBVYLRGTUFIJP-UHFFFAOYSA-N 7-(3-ethoxyphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound CCOC1=CC=CC(C=2C=C3N=C(C)C=C(C3=CC=2)N2CCCC2)=C1 GHBVYLRGTUFIJP-UHFFFAOYSA-N 0.000 description 1
FIDFSHUWBWHZJX-UHFFFAOYSA-N 7-(3-methoxyphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound COC1=CC=CC(C=2C=C3N=C(C)C=C(C3=CC=2)N2CCCC2)=C1 FIDFSHUWBWHZJX-UHFFFAOYSA-N 0.000 description 1
ISDPWFSPAQGKSQ-UHFFFAOYSA-N 7-(4-ethenylphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=CC(C=C)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 ISDPWFSPAQGKSQ-UHFFFAOYSA-N 0.000 description 1
AVRUMGAVADBWCO-UHFFFAOYSA-N 7-(4-ethylphenyl)-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C1=CC(CC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 AVRUMGAVADBWCO-UHFFFAOYSA-N 0.000 description 1
JMHTXMNDDGOVFI-UHFFFAOYSA-N 7-(4-methoxyphenyl)-2-methyl-4-piperidin-1-ylquinazoline Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=NC(C)=N2)N3CCCCC3)C2=C1 JMHTXMNDDGOVFI-UHFFFAOYSA-N 0.000 description 1
GYJQXGHGCCYCJU-UHFFFAOYSA-N 7-(4-methoxyphenyl)-2-methyl-4-piperidin-1-ylquinoline Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCCC3)C2=C1 GYJQXGHGCCYCJU-UHFFFAOYSA-N 0.000 description 1
OLVRFWPQQQINIU-UHFFFAOYSA-N 7-(4-methoxyphenyl)-2-methyl-4-pyrrolidin-1-ylquinazoline Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=NC(C)=N2)N3CCCC3)C2=C1 OLVRFWPQQQINIU-UHFFFAOYSA-N 0.000 description 1
FLHKIOOREATBEI-UHFFFAOYSA-N 7-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-4-pyrrolidin-1-ylquinoline Chemical compound C=12C=CC(C=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)=CC2=NC(C)=CC=1N1CCCC1 FLHKIOOREATBEI-UHFFFAOYSA-N 0.000 description 1
CMVNWVONJDMTSH-UHFFFAOYSA-N 7-bromo-2-methyl-1h-quinazolin-4-one Chemical compound C1=CC(Br)=CC2=NC(C)=NC(O)=C21 CMVNWVONJDMTSH-UHFFFAOYSA-N 0.000 description 1
PIRMWSIKQIRGGV-UHFFFAOYSA-N 7-bromo-2-methyl-4-piperidin-1-ylquinazoline Chemical compound C=12C=CC(Br)=CC2=NC(C)=NC=1N1CCCCC1 PIRMWSIKQIRGGV-UHFFFAOYSA-N 0.000 description 1
HFGNSNIHDQZMCZ-UHFFFAOYSA-N 7-bromo-2-methyl-4-pyrrolidin-1-ylquinazoline Chemical compound C=12C=CC(Br)=CC2=NC(C)=NC=1N1CCCC1 HFGNSNIHDQZMCZ-UHFFFAOYSA-N 0.000 description 1
UQGLZUPLSAZMLO-UHFFFAOYSA-N 7-bromo-4-chloro-2-methylquinazoline Chemical compound C1=CC(Br)=CC2=NC(C)=NC(Cl)=C21 UQGLZUPLSAZMLO-UHFFFAOYSA-N 0.000 description 1
RVFHEYHUJKJJRV-UHFFFAOYSA-N 7-bromo-4-pyrrolidin-1-ylquinoline Chemical compound C=1C=NC2=CC(Br)=CC=C2C=1N1CCCC1 RVFHEYHUJKJJRV-UHFFFAOYSA-N 0.000 description 1
XZHCCTUWRMLRIC-UHFFFAOYSA-N 7-bromo-n,n,2-trimethylquinazolin-4-amine Chemical compound BrC1=CC=C2C(N(C)C)=NC(C)=NC2=C1 XZHCCTUWRMLRIC-UHFFFAOYSA-N 0.000 description 1
PGIGGIKZCRATES-UHFFFAOYSA-N 7-bromo-n-butyl-2-methylquinazolin-4-amine Chemical compound BrC1=CC=C2C(NCCCC)=NC(C)=NC2=C1 PGIGGIKZCRATES-UHFFFAOYSA-N 0.000 description 1
RAARJFUHNRWQCS-UHFFFAOYSA-N 7-iodo-2-methyl-4-(4-methylpiperazin-1-yl)quinoline Chemical compound C1CN(C)CCN1C1=CC(C)=NC2=CC(I)=CC=C12 RAARJFUHNRWQCS-UHFFFAOYSA-N 0.000 description 1
CVGUFBIOFQLRII-UHFFFAOYSA-N 7-iodo-2-methyl-4-piperidin-1-ylquinoline Chemical compound C=12C=CC(I)=CC2=NC(C)=CC=1N1CCCCC1 CVGUFBIOFQLRII-UHFFFAOYSA-N 0.000 description 1
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010046593 Neuropeptide Y5 receptor Proteins 0.000 description 1
229940116685 Neuropeptide receptor antagonist Drugs 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
108010002747 Pfu DNA polymerase Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
238000006619 Stille reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
238000006069 Suzuki reaction reaction Methods 0.000 description 1
WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
230000036528 appetite Effects 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
125000006267 biphenyl group Chemical group 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
YAFMKOTWDFATRM-UHFFFAOYSA-N ethyl 3-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C=C3N=C(C)C=C(C3=CC=2)N2CCCC2)=C1 YAFMKOTWDFATRM-UHFFFAOYSA-N 0.000 description 1
PXFUMLPSNIKBBF-UHFFFAOYSA-N ethyl 3-(3-iodoanilino)but-2-enoate Chemical compound CCOC(=O)C=C(C)NC1=CC=CC(I)=C1 PXFUMLPSNIKBBF-UHFFFAOYSA-N 0.000 description 1
RDKPSHYXPQEQDN-UHFFFAOYSA-N ethyl 4-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 RDKPSHYXPQEQDN-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
238000011551 log transformation method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
BGMROBFFGQCSKY-UHFFFAOYSA-N n,n-diethyl-2-methyl-7-[3-(trifluoromethyl)phenyl]quinolin-4-amine Chemical compound C=1C=C2C(N(CC)CC)=CC(C)=NC2=CC=1C1=CC=CC(C(F)(F)F)=C1 BGMROBFFGQCSKY-UHFFFAOYSA-N 0.000 description 1
QWWQHPCBUMYRBZ-UHFFFAOYSA-N n,n-diethyl-7-iodo-2-methylquinolin-4-amine Chemical compound IC1=CC=C2C(N(CC)CC)=CC(C)=NC2=C1 QWWQHPCBUMYRBZ-UHFFFAOYSA-N 0.000 description 1
FPONLCTYVXUXDH-UHFFFAOYSA-N n,n-dimethyl-4-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)aniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 FPONLCTYVXUXDH-UHFFFAOYSA-N 0.000 description 1
GMKFJNALMSBBIW-UHFFFAOYSA-N n-[2-methyl-4-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)phenyl]acetamide Chemical compound C1=C(C)C(NC(=O)C)=CC=C1C1=CC=C(C(=NC(C)=N2)N3CCCC3)C2=C1 GMKFJNALMSBBIW-UHFFFAOYSA-N 0.000 description 1
YRQDRBFQYSCCKW-UHFFFAOYSA-N n-[3-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C=C3N=C(C)C=C(C3=CC=2)N2CCCC2)=C1 YRQDRBFQYSCCKW-UHFFFAOYSA-N 0.000 description 1
QZACFLRXNVJUDK-UHFFFAOYSA-N n-[4-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 QZACFLRXNVJUDK-UHFFFAOYSA-N 0.000 description 1
NMSYJCVDQFWOPT-UHFFFAOYSA-N n-methyl-4-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 NMSYJCVDQFWOPT-UHFFFAOYSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
125000000369 oxido group Chemical group [*]=O 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000008188 pellet Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
HZFPPBMKGYINDF-UHFFFAOYSA-N pyrimidin-5-ylboronic acid Chemical compound OB(O)C1=CN=CN=C1 HZFPPBMKGYINDF-UHFFFAOYSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
150000003246 quinazolines Chemical class 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
238000007614 solvation Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
PJFRGDYWYNVWPC-UHFFFAOYSA-N tert-butyl n-[4-(2-methyl-4-pyrrolidin-1-ylquinazolin-7-yl)phenyl]carbamate Chemical compound C=12C=CC(C=3C=CC(NC(=O)OC(C)(C)C)=CC=3)=CC2=NC(C)=NC=1N1CCCC1 PJFRGDYWYNVWPC-UHFFFAOYSA-N 0.000 description 1
238000010257 thawing Methods 0.000 description 1
230000035924 thermogenesis Effects 0.000 description 1
ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
238000001890 transfection Methods 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200301719A 2000-09-06 2003-02-28 Quinoline and quinazoline derivatives as ligands for the neuropeptide Y receptor. ZA200301719B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP00119262		2000-09-06

Publications (1)

Publication Number	Publication Date
ZA200301719B true ZA200301719B (en)	2004-06-22

Family

ID=8169763

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200301719A ZA200301719B (en)	2000-09-06	2003-02-28	Quinoline and quinazoline derivatives as ligands for the neuropeptide Y receptor.

Country Status (16)

Country	Link
US (2)	US6900226B2 (fr)
EP (1)	EP1318981A2 (fr)
JP (1)	JP2004508357A (fr)
KR (1)	KR100621272B1 (fr)
CN (1)	CN1274676C (fr)
AR (1)	AR030596A1 (fr)
AU (2)	AU1047402A (fr)
BR (1)	BR0113710A (fr)
CA (1)	CA2420703A1 (fr)
GT (1)	GT200100183A (fr)
MX (1)	MXPA03001928A (fr)
PA (1)	PA8528401A1 (fr)
PE (1)	PE20020485A1 (fr)
UY (1)	UY26926A1 (fr)
WO (1)	WO2002020488A2 (fr)
ZA (1)	ZA200301719B (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE387428T1 (de) *	2001-05-21	2008-03-15	Hoffmann La Roche	Chinolinderivate als liganden für den neuropeptid-y-rezeptor
GB0121709D0 (en) *	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
BR0212985A (pt) *	2001-09-24	2005-08-30	Imp College Innovations Ltd	Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
US6787558B2 (en) *	2001-09-28	2004-09-07	Hoffmann-La Roche Inc.	Quinoline derivatives
US8058233B2 (en) *	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
MXPA04007502A (es)	2002-02-04	2004-11-10	Hoffmann La Roche	Derivados de quinolina como antagonistas de neuropeptido y (npy).
NZ534757A (en)	2002-03-12	2006-07-28	Merck & Co Inc	Substituted amides
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
BR0312461A (pt)	2002-07-05	2005-04-26	Hoffmann La Roche	Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e métodos para tratamento e profilaxia
CA2493712A1 (fr)	2002-08-07	2004-02-19	F. Hoffmann-La Roche Ag	Derives d'aminothiazole pouvant servir d'inhibiteurs de recepteur npy5
WO2004052862A1 (fr) *	2002-12-10	2004-06-24	Ono Pharmaceutical Co., Ltd.	Composes heterocycliques contenant de l'azote et leur utilisation medicale
US7166575B2 (en) *	2002-12-17	2007-01-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2004080463A1 (fr) *	2003-03-10	2004-09-23	Schering Corporation	Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese
JP4887139B2 (ja) *	2003-03-25	2012-02-29	武田薬品工業株式会社	ジペプチジルペプチダーゼインヒビター
BRPI0413452A (pt)	2003-08-13	2006-10-17	Takeda Pharmaceutical	composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
US7790734B2 (en)	2003-09-08	2010-09-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CA2551037A1 (fr)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	Nouveau derive de piperidine
TWI344364B (en)	2003-11-10	2011-07-01	Synta Pharmaceuticals Corp	Fused heterocyclic compounds
CN102134231B (zh)	2004-03-15	2020-08-04	武田药品工业株式会社	二肽基肽酶抑制剂
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
US8283354B2 (en) *	2004-09-02	2012-10-09	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
US7718658B2 (en) *	2004-09-02	2010-05-18	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
WO2006050843A1 (fr) *	2004-11-09	2006-05-18	F. Hoffmann-La Roche Ag	Composes aminoquinazolines
EP2805953B1 (fr)	2004-12-21	2016-03-09	Takeda Pharmaceutical Company Limited	Inhibiteurs de peptidase dipeptidyl
US8138206B2 (en)	2005-05-30	2012-03-20	Msd. K.K.	Piperidine derivative
GB0511986D0 (en) *	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
WO2007018248A1 (fr)	2005-08-10	2007-02-15	Banyu Pharmaceutical Co., Ltd.	Composé de pyridone
DE602006017712D1 (de)	2005-08-24	2010-12-02	Banyu Pharma Co Ltd	Phenylpyridonderivat
JPWO2007029847A1 (ja)	2005-09-07	2009-03-19	萬有製薬株式会社	二環性芳香族置換ピリドン誘導体
CA2622472C (fr)	2005-09-14	2013-11-19	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
CN102675221A (zh)	2005-09-16	2012-09-19	武田药品工业株式会社	用于制备嘧啶二酮衍生物的方法中的中间体
KR20080059233A (ko)	2005-10-21	2008-06-26	노파르티스 아게	레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
EP1944301A4 (fr)	2005-10-27	2012-01-04	Msd Kk	Nouveau derive de benzoxathiine
ES2381205T3 (es)	2005-11-10	2012-05-24	Msd K.K.	Derivado espiro aza-sustituido
US7678803B2 (en) *	2006-08-24	2010-03-16	Serenex, Inc.	Quinazoline derivatives for the treatment of cancer
US8027888B2 (en) *	2006-08-31	2011-09-27	Experian Interactive Innovation Center, Llc	Online credit card prescreen systems and methods
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
AU2007301126A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TWI428346B (zh) *	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
PE20090717A1 (es) *	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
CA2688161C (fr)	2007-06-04	2020-10-20	Kunwar Shailubhai	Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2264026A4 (fr)	2008-03-06	2012-03-28	Msd Kk	Dérivé d'alkylaminopyridine
JPWO2009119726A1 (ja)	2008-03-28	2011-07-28	Ｍｓｄ株式会社	メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (fr)	2008-06-04	2018-06-26	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
AU2009261248A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diarylketoxime derivative
JP2011528375A (ja)	2008-07-16	2011-11-17	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20110124674A1 (en)	2008-07-30	2011-05-26	Hiroyuki Kishino	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
EP2348018A4 (fr)	2008-09-25	2012-04-25	Kyorin Seiyaku Kk	Dérivé biarylique hétérocyclique et inhibiteur de pde le renfermant en tant qu'ingrédient actif
US20110224250A1 (en) *	2008-10-09	2011-09-15	Yasushi Kohno	Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
MX2011004258A (es)	2008-10-22	2011-06-01	Merck Sharp & Dohme	Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20110230399A1 (en) *	2008-11-25	2011-09-22	Bowen Richard L	Methods for Treating Obesity Related Disease
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP3243385B1 (fr)	2011-02-25	2021-01-13	Merck Sharp & Dohme Corp.	Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
MX343893B (es)	2011-11-04	2016-11-28	Hoffmann La Roche	Nuevos derivados de aril-quinolina.
AU2013296470B2 (en)	2012-08-02	2016-03-17	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
KR101415806B1 (ko)	2012-08-22	2014-07-09	한국화학연구원	퀴놀린 유도체를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물
EP2958562A4 (fr)	2013-02-22	2016-08-10	Merck Sharp & Dohme	Composés bicycliques antidiabétiques
US9650375B2 (en)	2013-03-14	2017-05-16	Merck Sharp & Dohme Corp.	Indole derivatives useful as anti-diabetic agents
CA2905435A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions utiles pour le traitement de troubles gastro-intestinaux
EP2970384A1 (fr)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase et leurs utilisations
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Composés tricycliques antidiabétiques
MX2017002610A (es)	2014-08-29	2017-10-11	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
US9353093B2 (en)	2014-10-07	2016-05-31	Allergan, Inc.	Indole-1-carboxamides as kinase inhibitors
AR109950A1 (es)	2016-10-14	2019-02-06	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
EP3551176A4 (fr)	2016-12-06	2020-06-24	Merck Sharp & Dohme Corp.	Composés hétérocycliques antidiabétiques
US10968232B2 (en)	2016-12-20	2021-04-06	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
TW202033516A (zh)	2018-11-20	2020-09-16	義大利商Ｔｅｓ製藥（股份）責任有限公司	α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
CN109897874A (zh) *	2019-03-25	2019-06-18	苏州同力生物医药有限公司	一种制备手性异喹啉羧酸的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4012513A (en) *	1971-11-03	1977-03-15	Imperial Chemical Industries Limited	Indole derivatives for providing analgesic and anti-inflammatory effects
CA1247547A (fr)	1983-06-22	1988-12-28	Paul Hadvary	Derives de leucine
CA1328881C (fr)	1984-12-21	1994-04-26	Pierre Barbier	Procede pour la fabrication d'oxetanones
CA1270837A (fr)	1984-12-21	1990-06-26	Hoffmann-La Roche Limited	Oxetanones
JPH068292B2 (ja)	1985-05-07	1994-02-02	アルカロイダベギエスゼティギャル	トリアゾリルキノリン誘導体
CA2035972C (fr)	1990-02-23	2006-07-11	Martin Karpf	Procede de preparation d'oxetanones
DE69111077T2 (de) *	1990-11-06	1995-11-02	Pfizer	Chinazolinderivate um die antitumorwirkung zu verbessern.
US5274143A (en)	1991-07-23	1993-12-28	Hoffmann-La Roche Inc.	Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
KR0144833B1 (ko) *	1992-12-28	1998-07-15	김태훈	신규의 퀴나졸린 유도체 및 그의 제조방법
WO1994019342A1 (fr) *	1993-02-18	1994-09-01	Kyowa Hakko Kogyo Co., Ltd.	Inhibiteur de l'incorporation d'adenosine
CA2203912A1 (fr)	1995-09-01	1997-03-13	Dennis Michael Zimmerman	Antagonistes du recepteur du neuropeptide y indolyle
US6004996A (en)	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
KR20010079636A (ko)	1998-08-14	2001-08-22	프리돌린 클라우스너, 롤란드 비. 보레르	라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
FR2795726A1 (fr)	1999-06-30	2001-01-05	Aventis Cropscience Sa	Nouveaux pyrazoles fongicides
AR028782A1 (es) *	2000-07-05	2003-05-21	Taisho Pharmaceutical Co Ltd	Derivados heterociclicos tetrahidropiridino o piperidino
US7074794B2 (en)	2000-08-10	2006-07-11	Mitsubishi Pharma Corporation	Proline derivatives and the use thereof as drugs
US6576644B2 (en) *	2000-09-06	2003-06-10	Bristol-Myers Squibb Co.	Quinoline inhibitors of cGMP phosphodiesterase
SE0004054D0 (sv) *	2000-11-06	2000-11-06	Astrazeneca Ab	N-type calcium channel antagonists for the treatment of pain
ATE387428T1 (de) *	2001-05-21	2008-03-15	Hoffmann La Roche	Chinolinderivate als liganden für den neuropeptid-y-rezeptor
US6787558B2 (en) *	2001-09-28	2004-09-07	Hoffmann-La Roche Inc.	Quinoline derivatives
MXPA04007502A (es) *	2002-02-04	2004-11-10	Hoffmann La Roche	Derivados de quinolina como antagonistas de neuropeptido y (npy).
BR0312204A (pt) *	2002-06-27	2005-04-26	Schering Ag	Antagonista de receptor ccr5 de quinolina substituìda
BR0312461A (pt) *	2002-07-05	2005-04-26	Hoffmann La Roche	Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e métodos para tratamento e profilaxia

2001
- 2001-08-27 US US09/939,883 patent/US6900226B2/en not_active Expired - Fee Related
- 2001-08-30 CN CNB018134610A patent/CN1274676C/zh not_active Expired - Fee Related
- 2001-08-30 BR BR0113710-7A patent/BR0113710A/pt not_active IP Right Cessation
- 2001-08-30 JP JP2002525110A patent/JP2004508357A/ja active Pending
- 2001-08-30 EP EP01978324A patent/EP1318981A2/fr not_active Withdrawn
- 2001-08-30 AU AU1047402A patent/AU1047402A/xx active Pending
- 2001-08-30 CA CA002420703A patent/CA2420703A1/fr not_active Abandoned
- 2001-08-30 MX MXPA03001928A patent/MXPA03001928A/es not_active Application Discontinuation
- 2001-08-30 WO PCT/EP2001/010014 patent/WO2002020488A2/fr not_active Application Discontinuation
- 2001-08-30 AU AU2002210474A patent/AU2002210474B2/en not_active Ceased
- 2001-08-30 KR KR1020037003252A patent/KR100621272B1/ko not_active IP Right Cessation
- 2001-09-04 PA PA20018528401A patent/PA8528401A1/es unknown
- 2001-09-04 AR ARP010104191A patent/AR030596A1/es unknown
- 2001-09-05 PE PE2001000891A patent/PE20020485A1/es not_active Application Discontinuation
- 2001-09-05 UY UY26926A patent/UY26926A1/es not_active Application Discontinuation
- 2001-09-05 GT GT200100183A patent/GT200100183A/es unknown
2003
- 2003-02-28 ZA ZA200301719A patent/ZA200301719B/en unknown
2005
- 2005-04-07 US US11/100,938 patent/US7265125B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BR0113710A (pt)	2003-06-03
AU1047402A (en)	2002-03-22
CN1444563A (zh)	2003-09-24
AR030596A1 (es)	2003-08-27
US20050176698A1 (en)	2005-08-11
WO2002020488A3 (fr)	2002-05-16
KR100621272B1 (ko)	2006-09-13
PE20020485A1 (es)	2002-06-14
CN1274676C (zh)	2006-09-13
US20020052356A1 (en)	2002-05-02
KR20030027110A (ko)	2003-04-03
US7265125B2 (en)	2007-09-04
AU2002210474B2 (en)	2006-11-02
GT200100183A (es)	2002-05-23
JP2004508357A (ja)	2004-03-18
CA2420703A1 (fr)	2002-03-14
PA8528401A1 (es)	2002-09-30
WO2002020488A2 (fr)	2002-03-14
UY26926A1 (es)	2002-03-22
US6900226B2 (en)	2005-05-31
MXPA03001928A (es)	2003-06-19
EP1318981A2 (fr)	2003-06-18

Publication	Publication Date	Title
ZA200301719B (en)	2004-06-22	Quinoline and quinazoline derivatives as ligands for the neuropeptide Y receptor.
AU2002210474A1 (en)	2002-06-13	Quinoline and quinazoline derivatives as ligands for the neuropetide Y receptor
AU2002338896B2 (en)	2006-04-27	Quinoline derivatives as ligands for the neuropeptide Y receptor
EP0871448B1 (fr)	2005-03-02	Composes de quinazoline d'aryle et d'heteroaryle inhibant la tyrosine kinase du recepteur de csf-1r
RU2298002C2 (ru)	2007-04-27	Производные хинолина в качестве антагонистов npy
RU2300531C2 (ru)	2007-06-10	Хинолиновые производные в качестве антагонистов нейропептида y
JP2008507500A (ja)	2008-03-13	Ｃｎｓ障害治療のためのｐｄｅ１０インヒビターとしてのキナゾリン−４−イル−ピペリジン及びシンノリン−４−イル−ピペリジン誘導体
BG65086B1 (bg)	2007-02-28	Триазоли с допамин-d3 рецепторен афинитет
TW200819444A (en)	2008-05-01	Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors
JP2002522536A (ja)	2002-07-23	置換４−アミノ−２−アリールピリミジン、それらの製造、それらの使用およびそれらを含有する医薬製剤
US3600390A (en)	1971-08-17	Novel 5-phenyl imidazolidino(5,1-a)5h-quinazolines and process therefor
AU2003281346B2 (en)	2007-04-05	Quinazoline derivatives
KR19990067137A (ko)	1999-08-16	신규 피페라지닐알킬티오피리미딘 유도체, 이를 함유하는약제학적 조성물 및 신규 화합물을 제조하는 방법